Magdalena aiming to submit Investigational New Drug (IND) application in early 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications ...
Ketamine, a hallucinogenic drug approved as an anesthetic, has been used to treat adults with depression, PTSD and other conditions, and studied in youth with depression.